These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25177566)

  • 61. Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections.
    Pitman JP; Basavaraju SV; Shiraishi RW; Wilkinson R; von Finckenstein B; Lowrance DW; Marfin AA; Postma M; Mataranyika M; Smit Sibinga CT
    Transfusion; 2015 Jul; 55(7):1685-92. PubMed ID: 25727921
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pre-donation deferral of blood donors in a Brazilian blood bank: a 10-year experience.
    Dias PB; Lissa NM; Skare T; Fávero KB; Almeida PTR; Nisihara R
    Transfus Med; 2019 Dec; 29(6):448-453. PubMed ID: 31608541
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Donor deferral due to anemia: A tertiary care center-based study.
    Bahadur S; Pujani M; Jain M
    Asian J Transfus Sci; 2011 Jan; 5(1):53-5. PubMed ID: 21572718
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Giant Platelets in Platelet Donors - A Blessing in Disguise?
    Roy AD; Choudhury N; Ray D
    J Clin Diagn Res; 2015 Jun; 9(6):EC01-3. PubMed ID: 26266124
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence and predictors of adverse reactions in plateletpheresis donors with the perspective of donor safety in a tertiary care hospital of Northern India.
    Solanki A; Katharia R; Singh A; Chauhan A; Chandra T; Sonker A; Agarwal P
    Asian J Transfus Sci; 2020; 14(1):44-48. PubMed ID: 33162705
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Switching iron-deficient whole blood donors to plateletpheresis.
    O'Meara A; Infanti L; Sigle J; Stern M; Buser A
    Transfusion; 2012 Oct; 52(10):2183-8. PubMed ID: 22404849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Blood Donor Deferral among Students in Northern Japan: Challenges Ahead.
    Ngoma AM; Goto A; Nollet KE; Sawamura Y; Ohto H; Yasumura S
    Transfus Med Hemother; 2014 Jul; 41(4):251-6. PubMed ID: 25254020
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low hemoglobin deferral in blood donors.
    Mast AE
    Transfus Med Rev; 2014 Jan; 28(1):18-22. PubMed ID: 24332843
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Variant Creutzfeldt-Jakob disease deferral in Canada: impact of stop dates.
    O'brien SF; Fan W; Yi QL; Uzicanin S; Osmond L; Goldman M
    Blood Transfus; 2018 Jan; 16(1):26-31. PubMed ID: 28151391
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Educating donors about deferrals through the provision of tailored materials: Findings from a survey of deferred donors.
    Gemelli CN; Kruse SP; Thijsen A; Van Dyke N; Davison TE
    Transfusion; 2021 Mar; 61(3):822-829. PubMed ID: 33615506
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genetic variations of CD36 and low platelet CD36 expression - a risk factor for lipemic plasma donation in Taiwanese apheresis donors.
    Lo SC; Lin KH; Hsieh HH; Lin DT; Hu CY
    Vox Sang; 2016 Apr; 110(3):236-43. PubMed ID: 26528880
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative study of automated plateletpheresis using five different apheresis systems in a tertiary care hospital.
    Chaudhary R; Das SS; Khetan D; Ojha S; Verma S
    Transfus Apher Sci; 2009 Apr; 40(2):99-103. PubMed ID: 19237317
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Frequency and Causes of Deferral among Blood Donors Presenting to Combined Military Hospital Multan.
    Iqbal H; Tameez Ud Din A; Tameez Ud Din A; Chaudhary FMD; Younas M; Jamil A
    Cureus; 2020 Jan; 12(1):e6657. PubMed ID: 32082957
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ
    Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusion-related acute lung injury risk from apheresis platelets.
    Eder AF; Dy BA; O'Neill EM
    Transfusion; 2016 Jun; 56(6 Pt 2):1608-15. PubMed ID: 26830063
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Strategies to recruit plateletpheresis donors from a registry of HLA-typed, unrelated, bone marrow donors.
    Bolgiano DC; Smith S; Slichter SJ
    Transfusion; 1993 Aug; 33(8):675-8. PubMed ID: 8342236
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deferral pattern in voluntary blood donors on basis of low hemoglobin and effect of application of digital hemoglobinometer on this pattern.
    Mathur A; Shah R; Shah P; Harimoorthy V; Choudhury N
    Asian J Transfus Sci; 2012 Jul; 6(2):179-81. PubMed ID: 22988386
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of blood donor deferral in Jeddah, Saudi Arabia: Characteristics and causes.
    Abdelaal M; Anwar F
    J Pak Med Assoc; 2016 Nov; 66(11):1392-1395. PubMed ID: 27812054
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of plateletpheresis on total platelet count and mean platelet volume: A meta-analysis.
    Gil-Betancur A; Mantilla-Gutierrez CY; Cardona-Arias JA
    J Evid Based Med; 2020 Aug; 13(3):206-214. PubMed ID: 32615026
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An Analysis of Bone Donor Deferral Rates in Scotland - a 6-Year Study.
    Galea G
    Transfus Med Hemother; 2011 Dec; 38(6):373-378. PubMed ID: 22403521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.